You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content.
You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.
The BEXSERO Infant Brochure contains information about meningococcal B and how to protect infants who are most at risk of meningococcal disease.
The BEXSERO Teen Brochure contains information about meningococcal B and how to protect teens who are at risk of meningococcal disease.
BEXSERO (Multicomponent meningococcal group B vaccine) is for immunisation against invasive disease caused by N. meningitidis group B from 2 months of age or as per official recommendations. BEXSERO is a prescription medicine. It is funded as part of the National Immunisation Schedule for infants and children under 5, people aged 13-25 years in close-living situations, and for people who are close contacts of a meningococcal case, or who are at high risk due to reduced immune function. See Pharmaceutical Schedule for full funding criteria. BEXSERO is also available for private purchase – you will need to pay the full cost of this medicine. Normal doctor’s charges apply. A 0.5 mL dose contains 50 mcg of Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein, 50 mcg of Neisseria meningitidis Group B Neisseria Adhesin A protein, 50 mcg of Neisseria meningitidis Group B Factor H Binding Protein fusion protein, 25 mcg of Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 measured as amount of total protein containing the PorA P1.4. BEXSERO has risks and benefits. Ask your doctor if BEXSERO is right for you. Use strictly as directed. BEXSERO should not be administered if you or your child are hypersensitive to any component of this vaccine. Very common side effects: Infants, toddlers & children: eating disorders, sleepiness, unusual crying, headache, diarrhoea, vomiting, rash, fever (≥38°C), injection site reactions, irritability, arthralgia. Use paracetamol to prevent and reduce the risk of fever in children under the age of 2. Adolescents & Adults: headache, nausea, injection site reactions, malaise, myalgia, arthralgia. If you or your child have side effects, see your doctor. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2023 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.
©2023 GSK Group of companies or its licensor. All Rights Reserved. Registered office: Level 2, Generator @GridAKL, 12 Madden Street, Auckland 1010, New Zealand. For information regarding GSK products or to report an adverse event, please call Medical Information on 0800 808 500. This site is intended for NZ audience only.
TAPS NP18971-PM-NZ-BEX-WCNT-230006 Date of Approval: 02 2023 Date of Expiry 02 2025